In this issue:
Malignancy risk of non-biologic immunosuppressive therapies
Treatment-refractory psoriasis and super-responders to biologic treatment
Biologic drug levels and anti-drug antibodies in patients with psoriasis
Impact of secukinumab on clinical outcomes in psoriasis patients
New-onset atopic dermatitis and psoriasis in the same patients
Biologic therapy and development of psoriatic arthritis
Combination biologic therapy for recalcitrant psoriasis and psoriatic arthritis
Use of biologics and other systemic therapies during COVID-19
Please login below to download this issue (PDF)